Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.06. | DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger | 145 | GlobeNewswire (Europe) | NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company"), a multinational company operating across diverse industries including packaging, wealth management... ► Artikel lesen | |
23.06. | Impact Biomedical-Aktie steigt nach Fusionsvereinbarung mit Dr Ashleys | 11 | Investing.com Deutsch | ||
23.06. | Impact Biomedical stock soars after merger deal with Dr Ashleys | 1 | Investing.com | ||
23.06. | IMPACT BIOMEDICAL INC; Dr Ashleys Limited: Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger | 266 | GlobeNewswire (Europe) | A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical... ► Artikel lesen | |
23.06. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
28.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
21.03. | Impact BioMedical-Aktien steigen bei unerklärlicher Marktaktivität | 8 | Investing.com Deutsch | ||
21.03. | Impact BioMedical shares soar on unexplained market activity | 1 | Investing.com | ||
21.03. | Impact BioMedical-Aktie schwankt ohne erkennbaren Grund | - | Investing.com Deutsch | ||
21.03. | Impact BioMedical shares fluctuate without clear cause | 1 | Investing.com | ||
21.03. | Impact Biomedical Inc. Announcement Stock Activity/Pricing | 258 | GlobeNewswire (Europe) | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 705 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
21.03. | Why Impact Biomedical Inc. (IBO) Surged On Thursday? | 16 | Insider Monkey | ||
13.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 5 | SEC Filings | ||
26.02. | Impact BioMedical acquires air purifier firm Celios | 2 | Investing.com | ||
26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 339 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen | |
26.02. | Impact Biomedical Inc. Announces Acquisition of Celios, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality" | 1 | GlobeNewswire (USA) | ||
15.10.24 | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 227 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
26.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 215 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
17.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 279 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 43,970 | +0,23 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 47 auf 52 Euro angehoben und die Einstufung auf "Kaufen" belassen. Qiagen sei zurück auf dem Wachstumspfad, die operative... ► Artikel lesen | |
EVOTEC | 7,440 | +2,59 % | Evotec: Neue Reaktion auf die Warnung | Vor wenigen Tagen hat Evotec eine Umsatzwarnung publiziert. Das Biotech-Unternehmen rechnet für 2025 mit einem Umsatz von 760 Millionen Euro bis 800 Millionen Euro. Bisher ging man von 840 Millionen... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 54,47 | -0,95 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
ARCELLX | 70,59 | -1,01 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
BIONTECH | 96,95 | -0,41 % | Biotech-Pionier stellt Weichen für den nächsten Wachstumsschub: BioNTech Offensive in der Krebsforschung. | BioNTech treibt mit einer groß angelegten Partnerschaft und einer Übernahme seine Transformation voran. Der Fokus verschiebt sich deutlich von Pandemie-Geschäft hin zu innovativer Onkologie.Partnerschaft... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 55,65 | -6,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,540 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
89BIO | 9,535 | -0,57 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
CG ONCOLOGY | 25,860 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
DYNE THERAPEUTICS | 9,310 | 0,00 % | Dyne Therapeutics verlängert Finanzierungshorizont bei Fortschritten in wichtigen Medikamentenprogrammen | ||
RECURSION PHARMACEUTICALS | 6,300 | 0,00 % | Why Recursion Pharmaceuticals Stock Got Mashed on Monday | ||
ABSCI | 2,970 | 0,00 % | Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics | ||
BAVARIAN NORDIC | 31,570 | -0,38 % | AKTIE IM FOKUS: Evotec legen weiter zu - Positives Umfeld, Bavarian Nordic | FRANKFURT/KOPENHAGEN (dpa-AFX Broker) - Die Aktien von Evotec haben am Montag auf dem höchsten Stand seit Mitte Juni von positiven Nachrichten für die Branche profitiert. Zuletzt gewannen sie unter... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 18,270 | +2,12 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
SUMMIT THERAPEUTICS | 27,460 | -4,25 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald |